Moderna Receives FDA Approval for RSV Vaccine Based on Penn Technology
RSV is a highly contagious seasonal respiratory virus and a leading cause of lower respiratory tract infections and pneumonia.
Penn Arts and Sciences’ MindCORE Neuroimaging Facility at Pennovation Works
The machine is the centerpiece of the new Neuroimaging Facility where scientists will study the mind-brain connection in-depth.
Tech Talks: Bridging Academia and Innovation in Philadelphia’s Tech Hub
On April 24th, 2024, Penn hosted an event co-organized by the Mack Institute for Innovation Management and the City of Philadelphia Department of Commerce.
2023 President’s Prize Winners: Where They Are Now?
The 2023 President’s Innovation Prize (PIP) and President’s Engagement Prize (PEP) winners have each made significant strides over the course of the past year.
LNP Research from the Mitchell Lab is Highlighted in the Philadelphia Inquirer
Mike Mitchell, PhD, was interviewed recently by the Philadelphia Inquirer about his cutting-edge research in lipid nanoparticles (LNPs), which are crucial for delivering mRNA into the body's cells.
Penn’s CAR-T Treatment Shrank Brain Tumors in Patients in Clinical Trial
In a new early-stage clinical trial, a Penn-invented CAR-T treatment shrank brain tumors in seven patients with glioblastoma.
PA as an Innovation Leader: Challenges and Solutions in the face of a Growing Industry
Pennsylvania legislators are working on new ways to retain young residents who too often leave the region for opportunities after receiving their education within the state.
New Proposed Federal Guidelines Could Threaten Innovation
Recently proposed guidance could expand "march-in rights" under the Bayh-Dole Act, significantly impacting the development of products from federally funded research.
ToxiSense Develops Plant-Based Alternativeto Horseshoe Crab Blood
ToxiSense is developing a plant-based alternative to test for bacterial toxins in vaccines and medical devices, which could eliminate the current need for bloodletting of horseshoe crabs.
Linnaeus Therapeutics Awarded European Patent
Linnaeus Therapeutics, Inc. announced the issuance of EP patent 3823617 by the European Patent Office (EPO) covering the pharmaceutical composition of matter for their lead compound, LNS8801.